IRCT2016101730345N1 IRCT 2016-10-30 CHU de Poitiers Daptomycin at high dose for hemodialysis patient DaptoHD Pharmacokinetics and safety of high-dose intravenous daptomycin in infected hemodialysis patients 2011-08-31 anticipated 10 Complete https://irct.ir/trial/24137 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Pharmacokinetics. 0 (exploratory trials) Catheter related blood stream infection. Patient on hemodialysis (regimen 2/2/3) with suspected CRBSI will be treated with Daptomycin at 10mg/kg immediately after dialysis (2 minutes intravenous infusion). Area under curve for 48h (AUC48h), AUC72h, Cmax, C0.5h (30 min after infusion) and Cmin will be determined. Pharmacokinetics parameters will be documented during the first 3 Daptomycin injections with blood sampling at 2 min, 1h, 2h, 4h, 12h, 24h, 44h (immediately before the next dialysis) and at 48h (immediately after completion of dialysis and before the next dose) after each injection. A 72h point will be added if the interval between two subsequent hemodialysis sessions and therefore also the Daptomycin injection interval of Daptomycin is 72 h. Treatment will be adapted according to microbiological results.Treatment duration is determined by the investigator according to medical need and microbiology. Catheter removal will be determined by the investigator according to infection severity, microbiology when available (systematic removal in case of Candida or Pseudomonas aeruginosa infections), and possibilities to create another vascular access if needed (hemodialysis catheters being vital for these patients, a conservative approach can be used as described by ERA-EDTA guidelines in 2007 and the Infectious Diseases Society of America in 2009). If the catheter is left in place, antiseptic lock (taurolidin) will be used at the end of each hemodialysis session..